Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H32ClN5O2 |
Molecular Weight | 470.007 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4
InChI
InChIKey=VRBKIVRKKCLPHA-UHFFFAOYSA-N
InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB01149Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nefazodone.html
Sources: http://www.drugbank.ca/drugs/DB01149
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nefazodone.html
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. Within the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2274630
Curator's Comment: antidepressant
Originator
Sources: http://adisinsight.springer.com/drugs/800000656
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: http://www.drugbank.ca/drugs/DB01149 |
5.8 nM [Ki] | ||
Target ID: CHEMBL228 Sources: http://www.drugbank.ca/drugs/DB01149 |
290.0 nM [Ki] | ||
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9400006 |
5.5 nM [Ki] | ||
Target ID: CHEMBL2095158 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9400006 |
84.0 nM [Ki] | ||
Target ID: CHEMBL214 Sources: http://www.drugbank.ca/drugs/DB01149 |
52.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NEFAZODONE HYDROCHLORIDE Approved UseNefazodone hydrochloride tablets are indicated for the treatment of depression. When deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with Nefazodone hydrochloride treatment. In many cases, this would lead to the conclusion that other drugs should be tried first. Launch Date1.06358401E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1588 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
880 μg/L |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
415 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
276 μg/L |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6378 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
3213 μg × h/L |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
787 μg × h/L |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 h |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
5.7 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: hepatic cirrhosis Age Group: adult Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: renal impairment Age Group: adult Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Other AEs: Headaches, Dry mouth... Other AEs: Headaches (53%) Sources: Dry mouth (42%) Diarrhea (42%) |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Other AEs: Dry mouth, Nausea... Other AEs: Dry mouth (25%) Sources: Page: Table 1Nausea (22%) Dizziness (17%) Constipation (14%) Asthenia (11%) Light headedness (10%) Blurred vision (9%) Confusion (7%) Abnormal vision (7%) |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 2 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 2 |
Other AEs: Somnolence... |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Disc. AE: Nausea, Headache... AEs leading to discontinuation/dose reduction: Nausea (3.5%) Sources: Page: Table 1Headache (2.9%) Dizziness (1.9%) Somnolence (1.5%) Insomnia (1.5%) Asthenia (1.3%) Agitation (1.2%) |
200 mg single, oral Highest studied dose |
healthy, elderly n = 12 Health Status: healthy Age Group: elderly Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
200 mg single, oral Highest studied dose |
healthy, younger n = 12 Health Status: healthy Age Group: younger Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea and vomiting | 200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: hepatic cirrhosis Age Group: adult Sex: unknown Population Size: 12 Sources: |
|
Nausea and vomiting | 200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: renal impairment Age Group: adult Sex: unknown Population Size: 12 Sources: |
|
Diarrhea | 42% | 430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Dry mouth | 42% | 430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Headaches | 53% | 430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Light headedness | 10% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Asthenia | 11% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Constipation | 14% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Dizziness | 17% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Nausea | 22% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Dry mouth | 25% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Abnormal vision | 7% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Confusion | 7% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Blurred vision | 9% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Somnolence | 25% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 2 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 2 |
Agitation | 1.2% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Asthenia | 1.3% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Insomnia | 1.5% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Somnolence | 1.5% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Dizziness | 1.9% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Headache | 2.9% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Nausea | 3.5% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Nausea and vomiting | 200 mg single, oral Highest studied dose |
healthy, elderly n = 12 Health Status: healthy Age Group: elderly Sex: unknown Population Size: 12 Sources: |
|
Nausea and vomiting | 200 mg single, oral Highest studied dose |
healthy, younger n = 12 Health Status: healthy Age Group: younger Sex: unknown Population Size: 12 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
weak | ||||
yes [IC50 4.7 uM] | ||||
yes [IC50 9 uM] | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. | 1999 Jul |
|
Depression, sleep physiology, and antidepressant drugs. | 2001 |
|
Separation anxiety disorder in children and adolescents: epidemiology, diagnosis and management. | 2001 |
|
Algorithm for the treatment of chronic depression. | 2001 |
|
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. | 2001 |
|
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. | 2001 Apr |
|
[Serotonin-noradrenaline reuptake inhibitors(SNRIs)]. | 2001 Aug |
|
Opposite effects of nefazodone in two human models of anxiety. | 2001 Aug |
|
Comparison between two models of experimental anxiety in healthy volunteers and panic disorder patients. | 2001 Dec |
|
Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. | 2001 Feb |
|
Current trends in the development of new antidepressants. | 2001 Feb |
|
The 'dalhousie serotonin cocktail' for treatment-resistant major depressive disorder. | 2001 Jun |
|
Depression and anxiety disorders. | 2001 Jun |
|
Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. | 2001 Jun |
|
Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. | 2001 Mar |
|
Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder. | 2001 Mar |
|
Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. | 2001 May |
|
Nefazodone for chronic daily headache prophylaxis: an open-label study. | 2001 May |
|
Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. | 2001 May |
|
Possible interaction of zopiclone and nefazodone. | 2001 Nov |
|
Pharmacotherapy for post-traumatic stress disorder: a comprehensive review. | 2001 Oct |
|
An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. | 2001 Oct |
|
Antidepressants in social anxiety disorder. | 2001 Sep |
|
Clinically significant drug interactions with antidepressants in the elderly. | 2002 |
|
Overview of psychiatric disorders and the role of newer antidepressants. | 2002 |
|
Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression. | 2002 |
|
Prevalence of sexual dysfunction among newer antidepressants. | 2002 Apr |
|
Serzone. Beware of dangerous liver problems. | 2002 Apr |
|
Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. | 2002 Apr |
|
Nefazodone and liver damage. | 2002 Aug |
|
An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. | 2002 Dec 30 |
|
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. | 2002 Jan 15 |
|
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. | 2002 Jun |
|
Nefazodone treatment of dysthymic disorder an open, long-term, prospective pilot study. | 2002 May |
|
Pharmacological interactions of statins. | 2002 May |
|
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. | 2002 May |
|
Effects of smoked marijuana in healthy and HIV + marijuana smokers. | 2002 Nov |
|
Reversible penile priapism associated with nefazodone. | 2002 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/nefazodone.html
Initial dose: 200 mg orally per day in two divided doses
Maintenance dose: 300 to 600 mg orally per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20606004
In vitro biliary excretion of micafungin in humans and rats was reduced by 75% in the presence of the bile salt export pump (BSEP) inhibitor nefazodone (25 uM)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
||
|
WHO-ATC |
N06AX06
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
||
|
NDF-RT |
N0000175696
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
||
|
WHO-VATC |
QN06AX06
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
||
|
LIVERTOX |
NBK548179
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01149
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
DTXSID2023357
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
7247
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
31565
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | RxNorm | ||
|
59H4FCV1TF
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
59H4FCV1TF
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
m7793
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | Merck Index | ||
|
83366-66-9
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
1890
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
100000084127
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
SUB09180MIG
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
C051752
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
Nefazodone
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
4449
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL623
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
C61859
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
Nefazodone
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
5432
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY | |||
|
7494
Created by
admin on Fri Dec 15 16:29:51 UTC 2023 , Edited by admin on Fri Dec 15 16:29:51 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)